Jade Biosciences, Inc. (NASDAQ:JBIO) Given Average Rating of “Moderate Buy” by Brokerages

Jade Biosciences, Inc. (NASDAQ:JBIO) has received an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $19.00.

A number of research firms have recently commented on JBIO. Jefferies Financial Group began coverage on Jade Biosciences in a research report on Monday, July 14th. They set a “buy” rating and a $16.00 target price on the stock. Weiss Ratings reiterated a “sell (e)” rating on shares of Jade Biosciences in a research report on Friday. BTIG Research began coverage on Jade Biosciences in a research report on Thursday, October 9th. They set a “buy” rating and a $28.00 target price on the stock. Wedbush lifted their target price on Jade Biosciences from $17.00 to $18.00 and gave the stock an “outperform” rating in a research report on Thursday, August 14th. Finally, Wall Street Zen cut Jade Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th.

Institutional Trading of Jade Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Legal & General Group Plc purchased a new stake in Jade Biosciences in the 2nd quarter valued at approximately $29,000. Russell Investments Group Ltd. purchased a new stake in Jade Biosciences in the 2nd quarter valued at approximately $31,000. BNP Paribas Financial Markets purchased a new stake in Jade Biosciences in the 2nd quarter valued at approximately $32,000. Ameritas Investment Partners Inc. purchased a new stake in Jade Biosciences in the 2nd quarter valued at approximately $33,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in Jade Biosciences in the 2nd quarter valued at approximately $71,000.

Jade Biosciences Stock Performance

Jade Biosciences stock opened at $9.80 on Monday. Jade Biosciences has a 1-year low of $6.57 and a 1-year high of $105.00. The firm has a market capitalization of $319.77 million, a PE ratio of -0.32 and a beta of 1.07. The company has a fifty day simple moving average of $8.57.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.43).

Jade Biosciences Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.